Managing Local Language Regulatory Submissions

Few regulatory affairs heads would dispute the rising complexity of compliance and regulation in life sciences. Despite efforts to encourage consistency in international submissions, evolving priorities and variances in individual market demands are heaping the pressure on regulatory professio Powered by WPeMatico Continue reading Managing Local Language Regulatory Submissions

EMA Relocation Countdown: Some Industry Viewpoints

July 1, 2018 marked the start of the six-month countdown to the European Medicines Agency (EMA) relocation of its operations to Amsterdam. Worryingly, there remains little guidance or clarity from the EMA as to the implications of the move, and Brexit, on the pharma industry. Three industr Powered by WPeMatico Continue reading EMA Relocation Countdown: Some Industry Viewpoints

Can Trump Plan Serve as Model for What Ails Europe?

Now Donald Trump has at last made his pitch to tackle the challenge of paying for drugs in the US, speculation is rife about what the impact could be around the world and healthcare payers in Europe are combing through his 44-page blueprint to see if any of his ideas might be worth a try locally Powered by WPeMatico Continue reading Can Trump Plan Serve as Model for What Ails Europe?

The Chinese Pharmaceutical Industry: Winners and Losers 2017

Jin Zhang reviews the current fortunes of the Chinese pharmaceutical companies. Recently, East Money Information published their latest Chinese Top 500 company list of 2017. Among them, 42 pharmaceutical companies were listed and arranged into three distinctive tiers. So, who are t Powered by WPeMatico Continue reading The Chinese Pharmaceutical Industry: Winners and Losers 2017

The UK’s New Statutory Scheme for Pricing of Branded Medicines

With a new consultation from the UK s Department of Health proposing changes to the Statutory Scheme for Pricing of Branded Medicines essentially the back-stop to the voluntary Pharmaceutical Price Regulation Scheme (PPRS) what could this mean for negotiation of a successor to the 2014 PPRS? Powered by WPeMatico Continue reading The UK’s New Statutory Scheme for Pricing of Branded Medicines

Health Policy Problem Solver: Fumie Griego

Turning Ideological Challenges into Practical Solutions The Geneva, Switzerland-based International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents research-based pharmaceutical companies and associations across the globe. It has consultative status w Powered by WPeMatico Continue reading Health Policy Problem Solver: Fumie Griego

Brexit and the EMA: Bidding and Betting on an Uncertain Future

The end of July was the deadline for submissions from countries bidding to host the relocated European Medicines Agency (EMA) when the UK withdraws from the European Union (EU), and the competition was fierce in the final weeks of bid preparation. As many as 20 EU member states were likely to pu Powered by WPeMatico Continue reading Brexit and the EMA: Bidding and Betting on an Uncertain Future